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Lung cancer has a 5-year survival rate of 17% with current standard-of-care radiation and 
chemotherapies (1,2,4,8,9). Immune escape contributes to poor tumor clearance driving the 
development of therapies that promote anti-tumor immune responses (29-33). The cytotoxic T-
lymphocyte response distinguishes cancerous cells by the presentation of mutated endogenous 
antigens on MHC-1 molecules (26,29-33). Radiation therapy has been shown to increase MHC-1 
antigen presentation (22-23,30). It has been proposed that DNA-damage response signaling 
inhibits translation during radiation induced cell recovery resulting in a post-repair spike in 
translation and MHC-1 presentation (22-23,30). We hypothesize that ATM and ATR inhibition 
will disrupt the negative regulation of translation post-radiation to impact the rate of MHC-1 
presentation. Increasing antigen presentation before cell recovery from radiation damage may 
increase the magnitude of mutant antigens to stimulate anti-tumor CD8+ T-cell activation. 
This investigation attempted to monitor the impact of DNA-damage response inhibition on 
translation and subsequent MHC-1 presentation post-radiation at two levels. First, fluctuations in 
the intracellular peptide pool available for MHC-1 antigen loading was measured via the activity 
of Transporter associated with Antigen Processing (TAP) responsible for shuttling cytosolic 
peptides into the ER for MHC-1 antigen loading (20-2226). Fluorescence Recovery After 
Photobleaching (FRAP) of TAP1-mNeonGreen was used to calculate the lateral diffusion of TAP 
within the ER membrane as diffusion is inversely correlated to TAP activity. Second, MHC-1 cell 
surface presentation was measured via flow cytometry.   
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1.0   INTRODUCTION 
1.1  LUNG CANCER THERAPEUTICS 
In 2017, lung and bronchial cancer was the leading cause of cancer related death for both sexes 
(27% male, 25% male) in the United States, more than colorectal, prostate, and breast cancer 
combined (1,7,8). Approximately 85% of lung cancer patients have non-small cell lung cancer 
(NSCLC) (1,2,4,7,8,9). With current standard-of-care therapies, lung cancer has the second lowest 
five-year survival rate at approximately 17% highlighting the need for improved therapeutics 
(1,2,4,7,8,9). Early detected stage I and II lung cancer patients are eligible for surgical resection 
and may receive adjuvant therapy to improve tumor clearance (2,4,8). The majority of patients are 
diagnosed with advanced (stage III) or metastatic (stage IV) cancer and are ineligible for surgery 
as it would be too invasive. Treatment options for stage III and IV patients include radiation, 
chemotherapy, targeted therapy, immunotherapy, or a combination thereof (2,4,8).  
Standard-of-care cancer therapeutics attempt to target one or more of the ‘Hallmarks of 
Cancer’ which include six accepted functional capabilities and two enabling characteristics. The 
functional characteristics are sustained cellular proliferation, evasion of growth suppressors, 
resisting cell death, replicative immortality, angiogenesis, and an activate invasive or metastatic 
phenotype (19). Genome instability and tumor promoting inflammatory condition are considered 
enabling characteristics, or rather the environmental and genomic basis for the induction of the six 
functional characteristics through the mutation or dysregulation of cellular processes (19). 
Dysregulation of cellular energetics and immune evasion are recognized as emerging ‘hallmarks 
of cancer’ (19). 
2 
 
 Targeted therapies are small molecule compounds that have been identified and designed 
to target specific mutated, upregulated, or downregulated proteins in pathways involved in 
proliferation, evasion of growth suppressors, resisting cell death, angiogenesis, and metastasis. In 
NSCLC, the most commonly (10-35% of patients) mutated or upregulated growth stimulating 
pathway is the EGFR pathway (2,4,7,8). Small molecule ATP competitive inhibitors erlotinib, 
gefitinib, and afatinib target active site of the EGF receptor tyrosine kinase to inhibit tumor cell 
proliferation (4,2,7,8).  Kinase inhibitors crizotinib, certitinib, and alectinib, target the ALK active 
site in the EML4-ALK translocation mutant implicated in malignant transformation in lung cancer 
(2,4,7,8,11). BRAF kinase inhibitors dabrafenib and trametinib target the BRAF growth 
stimulating pathways (2,4,7,8). Anti-angiogenesis drugs, bevacizumab or ramucirumab, inhibit the 
VEGF signaling for new blood vessel formation in tumors (2,4,7,8). Targeted therapies selected 
to combat specific mutation profiles produce significant patient response; however, often patients 
experience a resurgence of more aggressive tumors containing resistance mutations that decrease 
targeted kinase inhibitor efficacy or upregulate compensatory growth pathways (2,4,7,810).  The 
development of resistance mutations is the constant uphill battle for pharmacologic development 
of new generations of kinase inhibitors, improving patient molecular screening, and clinical 
treatment.  
 Immunotherapies are an emerging branch of targeted therapies which inhibit tumor 
immune evasion by disrupting the signaling of immune inactivating signals. Lung cancer patients 
have demonstrated high success with emerging immunotherapies nivolumab and prembrolizumab 
which target the PD1/PD-L1 immune checkpoint which inhibits tumor cell activation of the 
cytotoxic-T lymphocytes (2,4,7,8,30-33). Patients with increased PD-L1 surface expression 
respond well and as these therapies target a receptor interaction, the development of resistance 
mutations is low. However, patients without PD-L1 expression profile are not as responsive 
reducing the effective population for this particular immunotherapy (30-33). 
 Considering the disadvantages of targeted therapy, chemotherapy remains a standard-of-
care for lung cancer patients (4,2,7,8). DNA damaging agents which intercalate into DNA 
(cisplatin, carboplatin) or inhibit topoisomerases (irinotecan, etoposide) induce the accumulation 
of lethal DNA lesions that stimulate cell death (2,4,7,8). Anti-metabolites (pemetrexed, 
gemcitabine) inhibit the generation of nucleic acids for DNA synthesis halting cell proliferation 
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(2,4,7,8).  Anti-microtubules (docetaxel, paclitaxel) inhibit cytoskeletal microtubule function 
preventing cell division and proliferation. Chemotherapy is administered as the primary treatment, 
adjuvant to surgery and radiation, or as a combination of chemotherapy (2,4,7,8). The main 
advantage to chemotherapy is that consistent patient responses can be achieved regardless of 
patient molecular profiles. However, these drugs have severe side effects due to the toxicity for 
normal tissues which significantly decrease the patient’s quality of life.  
 Radiation therapy, another standard treatment for lung cancer patients, utilizes the 
intersection of multiple high-energy particles or x-rays expose tumors to lethal doses of radiation 
while exposing surrounding tissues to sublethal doses (2,4,7,8). Radiation exposure causes direct 
and indirect (reactive radicals from radiolysis) damage to proteins, DNA, and cell organelles 
stimulating cell death. Radiation therapy does not rely on blood supply and therefore does not 
produce systemic toxicities, which is a major advantage. However, radiation therapy is not suitable 
for widespread cancers, and thus limited in benefit for advanced metastatic cancers. Often radiation 
therapy is combined with a chemical therapy to improve tumor clearance (2,4,7,8). 
 Research to improve standard-of-care therapies include combining DNA damaging agents 
with targeted DNA-damage response inhibitors (5, 12-18,35-47). Targeted DNA-damage response 
inhibition takes advantage of the genomic instability inherent in cancer to induce the accumulation 
of lethal amounts of DNA damage to stimulate cell death by inhibiting the signaling pathways that 
regulate DNA repair and cell cycle arrest. The simultaneous generation of DNA damage and 
inhibition of DNA-damage response pathways increases the accumulation and propagation of 
DNA damage through the cell cycle and ultimately induces cell death (12-18,35-47). The 
combination of these therapies can increase the therapeutic window to generate better patient 
responses with decreased side effects.  The investigation described in this thesis involves the study 
of how combing radiation with targeted DNA-damage response inhibition may also combat 
another ‘hallmark of cancer’ by impacting expression of activating immune response receptors.  
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1.2  TARGETING THE DNA DAMAGE RESPONSE IN CANCER 
The DNA-damage response is a network of enzymatic pathways that work in concert to detect, 
signal the presence of, and direct the repair of DNA lesions (12-18,35-47). Deficiencies in the 
DNA-damage response results in sensitivity to DNA damaging agents and are the cause of several 
human diseases (12-18,36,41-50). Ataxia telangiectasia mutated kinase (ATM) and Ataxia 
telangiectasia mutated-related kinase (ATR) are apical signaling kinases of the DNA-damage 
response (Figure 1 and 2). ATM and ATR are recruited to double-strand breaks (DSB) and RPA-
coated ssDNA, respectively. As signaling kinases, ATM and ATR phosphorylate a broad, 
overlapping spectrum of substrates to modulate several cellular processes including DNA 
replication, DNA repair, transcription, translation, cell cycle progression, apoptosis, and 
senescence (Figure 1 and 2) (12-18). 
DNA damage induced by radiation and DNA damaging chemotherapy activate both ATM 
and ATR (12-18,35-47). Double-strand breaks from radiation induce the activation of ATM or 
DNA-PK kinases to regulate homologous recombination (HR) or non-homologous end joining 
(NHEJ) DNA repair pathways, respectively (Figure 1) (12-18). Similarly, alkylating agents or 
crosslinking agents like Cisplatin that stall the replication fork progression generate RPA coated 
ssDNA which recruits and activates ATR kinase to regulate the replisome stability, origin firing, 
and repair (Figure 1) (12-18). In addition to regulating DNA repair, the DNA damage response 
kinases regulate cell cycle progression, apoptosis, and senescence. Inhibition of ATM or ATR 
leads to deficient G1/S, S, or G2/M checkpoints (Figure 2) (12-18,35-47). This causes DNA 
damage to be propagated through the cell cycle simulating replicative and/or mitotic catastrophe 
and cell death (12-18,35-47). Therefore, inhibiting both DNA repair and checkpoint signaling 
lowers the dose of damaging agents necessary to induce death by providing an easier environment 
for the accumulation of lethal amounts of DNA damage.  
Loss of ATM (ataxia telangiectasia mutated) in ataxia telangiectasia patients, and transient 
pharmacologic inhibition of ATM has been documented to sensitizes cells to radiation 
(35,37,40,41-46). ATR inhibitors have been observed to be well tolerated in vivo and sensitize 
lung cancer cells to cisplatin and IR (35-40). Due to the compensatory nature of the DNA-damage 
response, deficiencies in one pathway often provides sensitivity to inhibition of other pathways. 
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For example, ATM loss in cancer has been associated with increased ATR activity which provides 
a ‘synthetic lethal’ environment for ATR inhibition (35,37,40,41-46). The Bakkensit lab has 
published that ATR inhibition synergizes with cisplatin to kill ATM deficient lung cancer cells 
and xenografts (35). DNA-damage response inhibition potentiates DNA damage from radiation 
and chemotherapy agents like cisplatin, gemcitabine, or irinotecan through the cell cycle 
checkpoints to induce mitotic catastrophe thereby decreasing the IC50, lowering dosing 
concentration, and providing relief from toxic side effects associated with these standard-of-care 
(35,37,40,41-46). The DNA-damage response has been suggested to contribute to translation 
regulation especially post radiation (23,24). Translation levels modulate immune receptor 
expression and presentation. Inhibition of the DNA-damage response in combination with 
radiation; therefore, may provide a means to impact immune responses post-radiation therapy. 
Figure 1: DNA-Damage Response Activation and Regulation of DNA Repair 
DNA damage response signaling kinases, ATM and ATR, are activated at DNA double-
strand breaks and single-stranded DNA associated with stalled replication forks and 
resected double-strand breaks, respectively. Radiation induced double strand breaks 
stimulate the activation of ATM or DNA-PK kinases to regulate HR or NHEJ DNA repair 
pathways, respectively. Similarly, alkylating agents or crosslinking agents like Cisplatin 
that stall the replication fork progression generate RPA coated ssDNA which recruits and 
activate ATR kinase to regulate the replisome stability, origin firing, and repair. 
Inhibition of ATM and ATR leads to the accumulation of DNA damage. 
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1.3  THE ROLE OF MHC-1 CELL SURFACE PRESENTATION IN TUMOUR CELL 
RECOGNITION 
Major histocompatibility complex class one (MHC-1) molecules present cytosolic and nuclear 
protein fragments present within the cell at the cell surface (27-29). CD8+ T cells sample the 
presented MHC-1 antigen landscape to distinguish ‘self’ and ‘non-self’ antigens (27-30). In the 
event of recognition of ‘non-self’ antigen presentation, the cytotoxic T lymphocytic response is 
activated and leads to the clearance of the compromised cell (27-29). Within the context of cancer, 
presentation of antigens containing mutations stemming from the inherent genome instability or 
improper peptide ligations called ‘neo-antigens’ can trigger the cytotoxic T lymphocyte response 
against tumor cells (27, 30). Conversely, immune evasion is one of the hallmarks of cancer where 
tumor cells down regulate MHC-1 by increasing degradation or by increasing immune inactivating 
stimuli (e.g. PD-L1)(18,31-34). Current immunotherapy initiatives that target immune 
Figure 2: DNA-Damage Response Cell-Cycle Checkpoint Regulation 
The DNA-damage response kinases regulate cell cycle progression, apoptosis, and senescence. Inhibition 
of ATM or ATR leads to deficient G1/S, S, or G2/M checkpoints. This causes the damage to be propagated 
through the cell cycle simulating replicative and/or mitotic catastrophe and cell death. Cdc25A is 
phosphatase that dephosphorylates CDK2 allowing cell cycle progression. Phosphorylation by Chk1 or 
Chk2 stimulates Cdc25A degradation. allowing stabilization of CDKs and cell cycle arrest or senescence. 
ATM/Chk2 phosphorylation of p53 leads to apoptosis or cell cycle arrest.  
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deactivating receptors and have proven to be successful in NSCLC suggesting that treatment 
options that increase immune activating stimuli may improve tumor clearance (31-34). Similarly, 
increasing the prevalence of ‘neo-antigen’ presentation has been proposed as a method to stimulate 
anti-tumor immune responses (30-34).  
MHC-1 cell surface presentation is regulated by the concentration of suitable peptides for 
loading as most MHC-1 molecules are degraded by ER-associated protein degradation systems 
(ERAD) without antigen loading (27-29). Proteasomal degradation of existing, nascent, or 
defective proteins provides the intracellular peptide pool for antigen presentation (27-29). Peptides 
are transported into the ER via transporter associated with antigen processing (TAP) and are 
trimmed in ER lumen by ERAAP before loading by the peptide loading complex (21-23,27). The 
MHC-1 peptide loading complex is formed by the interaction of active TAP, unfolded MHC-1, 
and chaperone proteins tapasin, calreticulin, and ERp57 (27-29). Once loaded with a peptide, the 
-chaperones release MHC-1 to pass through the ER quality control checks to pass through the golgi
trafficking system to the cell surface (27-29).
Defective ribosomal products (or DRiPs) from defective transcription, translation, splicing, 
or failed complex assembly are degraded immediately by the proteasome to prevent aggregate 
formation. The immediate degradation of a fraction of newly synthesized proteins couples 
translation to MHC-1 presentation. Therefore, regulation of translation impacts the generation of 
an intracellular peptide pool for antigens. Viral infection, IFNgamma signaling, microRNA 
expression, and ionizing radiation exposure alter the antigen landscape by altering the amount and 
type of proteins being synthesized (23,24,27). Reits et al. has observed a dose dependent increase 
in MHC-1 presentation over several days post radiation exposure (23). The observed radiation 
induced increase in MHC-1 presentation was in part regulated by mTOR cap-dependent translation 
(21-24). This suggests that regulation of translation post-radiation can impact MHC-1 exposure. 
Radiation induced ATM signaling through mTOR has been observed to alter translation in 
transformed cell lines (24).  Increasing the rate of MHC-1 expression post-radiation exposure may 
potentially increase the amount of defective or mutated antigens to be expressed on the cell surface. 
For cancer therapeutics this may present an avenue for improving immune clearance of irradiate 
tumor cells.  
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1.4  REGULATION OF CAP-DEPENDENT TRANSLATION POST-RADIATION 
 
Cap-dependent translation is responsible for the majority of protein synthesis. The translation 
initiation complex forms when eukaryotic translation initiation factor 4F (eIF4F) binds the 5’ cap 
of the mRNA and recruits eIF4G and eIF4A (Figure3) (25,26). The binding of eIF4F is regulated 
by inhibitory 4E-binind protein 1 (4E-BP1) (25,26). Phosphorylation of 4E-BP1 induces 
disassociation from eIF4F allowing it to bind the 5’ cap of the mRNA (25,26). eIF4A is an RNA 
helicase that removes secondary structures prior to translation (Figure3). The binding of 
regulatory factor eIF4B enhances eIF4A activity. Phosphorylation of eIF4B increases the 
association of eIF4B and eIF4A increasing eIF4A helicase activity (Figure3) (25,26). eIF4G 
provides the molecular scaffolding for assembly of the 40s ribosomal subunit to the mRNA-eIF4F 
imitation complex (eIF4F, eIF4A- eIF4B, eIF4G) (25,26). Phosphorylation of eIF4G increases 
eIF4G binding to the eIF4F initiation complex. The phosphotransferase activity of mTORC1 
(mTOR, raptor, and LST8) regulates translation initiation by phosphorylating 4E-BP1 and the 40S 
ribosomal protein S6 kinases (S6Ks) (25,26).. 
 Braustein et al. (2009) observed that post-radiation the DNA-damage response signaling 
through the p53 pathway in transformed cells. Activation of the p53, the induction of Senestrin 1/2 
proteins, and activation of AMP kinase lead to the inhibition of mTOR (24). Inactive mTOR 
impedes the inactivation of 4E-BP1 and the phosphorylation of 40S ribosomal S6Ks decreasing 
cap-dependent translation. During cellular recovery, activation of the DNA-damage response 
ATM-p53 axis maintained cap-dependent translation inhibition (24). In non-transformed cells, 
radiation activates ERK1/2 resulting in transient mTOR regulated cap-dependent translation of 
DNA repair proteins and cell survival proteins (24). The role for ATR signaling in translation 
regulation was not elucidated. Reits et al. observed increased mTOR regulated translation and 
MHC-1 surface presentation post-radiation highlighting the potential for an DNA-damage 
response dependent impact on MHC-1 presentation via regulation of cap-dependent translation 
post-radiation (23). 
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1.5  OVERVIEW 
Protein synthesis is directly correlated with MHC-1 antigen presentation where ~1% of newly 
synthesized polypeptides are trafficked into the endoplasmic reticulum by transporter associated 
with antigen presentation (TAP) and loaded onto MHC-1 (21,23,27). Following radiation, antigen 
presentation results from the degradation of the damaged proteins (23,24). Subsequent DNA 
damage ATM signaling halts cap-dependent translation via inhibition of mTOR thereby promoting 
translation of select repair and survival proteins (23,24). After recovery, there is a burst of mTOR-
dependent translation to replace damaged proteins (23,24,26). The role of ATR in the regulation 
of translation has not been explored. Furthermore, the impact of ATM and ATR inhibitors on 
MHC-1 antigen presentation has not been investigated.  
Peptides presented by MHC-1 provide the “self-recognition” signal to cytotoxic T-
lymphocytes. In the context of cancer, peptides from mutant proteins are called “neo-antigens” 
(23,24,27,30). Increased presentation of neo-antigens on the cell surface by MHC-1 has been 
implicated in increasing the immunogenicity of tumor cells (27-30). Our objective is to determine 
the impact of ATM and ATR kinase inhibitors on MHC-1 antigen presentation in lung cancer. Our 
rationale is that ATR or ATM inhibition increasing the rate of MHC-1 presentation in irradiated 
lung tumors will improve anti-tumor immune response. We hypothesize that ATM and ATR 
inhibitors disrupt the inhibitory regulation of protein translation impact MHC-1 presentation and 
potentially the frequency of neo-antigens after ionizing radiation. 
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2.0   MATERIALS AND METHODS 
2.1  TAP1-mNEONGREEN CLONING 
A mammalian expression vector was generated to express human spliced variant 1 of Transporter 
associated with Antigen Processing subunit one (TAP1) with C-terminal monomeric fluorophore 
NeonGreen (B. lanceolatum)(20-22). Simon Watkins, PhD. of the Center for Biological Imaging 
at the University of Pittsburgh provided an aliquot of the mNeonGreen-N1 mammalian expression 
vector. pcDNA3.1-TAP1-GFP expression vector was purchased from GenScript. Utilizing unique 
BamHI and EcoI restriction enzyme sites, the TAP1 gene was amplified by PCR and inserted into 
the mNeonGreen-N1 vector to generate the TAP1-mNeonGreen vecto
2.2  TAP1-mNEONGREEN U2OS STABLE LINE GENERATION 
The TAP1-mNeonGreen vector provides neomycin resistance in positive cells for selection. 
Osteosarcoma U2OS cells in RPMI supplemented with 10% fetal bovine serum and 5% penicillin 
streptomycin were transiently transfected with Lipofectamine2000 (ThermoFisher) in a 1:5 DNA 
to lipid ratio. Transfection of 2ug pEYFP was used as a positive control for of 2ug of TAP1-
mNeonGreen transfection. 48hr post-transfection EYFP and TAP1-mNeonGreen expression was 
confirmed via standard fluorescence microscopy. Growth media was exchanged for selection 
media containing 500ug/mL G418 (Invitrogen) refreshed at 24hrs and every subsequent 48hrs with 
replating as necessary (6). Upon elimination of the non-transfected control population, limited 
dilution cloning of the TAP1-mNeonGreen positive cell population was used to isolate stable line 
with a medium TAP1-NeonGreen fluorescent phenotype for experimentation.   
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2.3  FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING OVERVIEW 
Fluorescence Recovery After Photobleaching (FRAP) is a method to quantify the mobile fraction 
and the rate of mobility of molecules within a cellular region (21-23). The molecule of interest is 
fluorescently tagged (e.g. TAP1-mNeonGreen) and using a high-powered laser a small region of 
interest is irreversibly photo-bleached. Diffusion of mobile non-bleached molecules from the 
surrounding area leads to a recovery of fluorescence intensity within the region of interest (21-23). 
Figure 4 demonstrates a typical TAP1-mNeonGreen FRAP experiment. Initial fluorescence 
intensity (Fi) of the region of interest is measured before photobleaching decreases the 
fluorescence intensity to the minimum (Fo). Over time fluorescence intensity is recovered by the 
diffusion of non-bleached TAP1-mNeonGreen molecules (mobile fraction). The time required to 
reach half the maximum recovery(Fmax) is the τD. The difference between the maximum 
fluorescence recovery (Fmax) and the initial fluorescence (Fi) is the immobile fraction of bleached 
TAP1-NeonGreen molecules within the region of interest. Unidirectional flow within a two-
dimensional system, such as a membrane, is due to Brownian motion and can be calculated 
D=ω2γ/4τD, where ω2 is the area of ROI and γ is the bleaching correction dependent on the laser 
profile (21-23). 
2.4  TAP1-mNEONGREEN LIVE CELL FRAP IMAGING 
Confocal analysis of living cells was performed with a Nikon Spectral A1 microscope with a live 
cell environmental chamber set at 37oC with constant CO2 exposure. TAP-mNeonGreen U2OS 
stable cells were plated on MatTek confocal plates for ~50% density at 24hr prior to imaging. Cells 
were treated at the indicated times with KU33599 (10uM), CHX (200uM), MG132 (10uM) or 
DMSO vehicle (0.1%) immediately prior to 2Gy or 5Gy radiation in a 137Cs irradiator. 30minutes 
post treatment the endoplasmic reticulum was bleached via spot stimulation for 15s with a 488nm 
laser (75output, 60x objective, 1.4NA, 500Hz, HV(G) 80, 39.6um pinhole, 1/6FPS). Imaging with 
continuous acquisition for 5min post photobleaching measured the fluorescence recovery within 
the region of interest. 
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2.5  DIFFUSION COEFICIENT DATA ANALYSIS 
NIS-Elements4.0 software monitored the fluorescence intensity over time within the defined 
region of interest while imaging. Post-data acquisition, the time of photobleaching was defined for 
the NIS-Elements4.0 FRAP analysis software to calculate the rate of recovery (τD). To account for 
differences in ROI area, the lateral diffusion coefficient (D) for each cell was calculated 
independently as D=ω2γ/4τD, where ω2 is the area of ROI and γ is the bleaching correction (21-
23). The average diffusion coefficient of at least 30 technical replicates for each treatment 
condition from three biological replicates was calculated and depicted as a mean +/- s.d. Statistical 
significance was determined using GraphPad Prism 7 by ANOVA with Tukey’s multiple 
comparison tests (95% confidence interval). 
Figure 4: Representative Fluorescence Recovery After 
Photobleaching (FRAP)  
Live-cell TAP1-NeonGreen U2OS stable cell imaging performed with a 
Nikon A1 Spectral Confocal microscope. Region of Interest (ROI) was 
bleached with 488nm laser for 30s (75output, 500Hz, 1.4NA, 39.6um 
pinhole,1/6FPS) and imaged every 15s for 5mins to capture recovery. 
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2.6  ANALYSIS OF MHC-1 CELL SURFACE PRESENTATION BY FLOW 
CYTOMETRY 
A549 and H460 lung adenocarcinoma cells were treated with AZD6738 (10uM or 1uM), or DMSO 
vehicle (0.1%) at the indicated times with respect to 2Gy radiation in a 137Cs irradiator. Treatment 
with MG132 (10uM) and CHX (200uM) was performed in the final 4hr of the treatment period. 
Cells were harvested for MHC-1 surface presentation at 4, 24, or 48hr post treatment in 
RPMI/10%FBS/5%PenStrep or DMEM/10%FBS/5%PenStrep, respectively. Cell pellets collected 
via centrifugation at 1,200xg for 5mins were washed 2x with FACS buffer (1xPBS+2%FBS). For 
surface MHC-1 presentation, live cells were stained in the dark for 30mins at 4o with a mouse 
FITC-conjugated anti-HuHLA-I (Invitrogen) at 1:300 or mouse anti-IgG2a isotype control 
(Pierce) at 1:100 antibodies at in FACS buffer. Cells were washed 3x in FACS buffer. Flow 
cytometry analysis was performed with the Accuri C6 cytometer (BD Biosciences) equipped with 
the CFlow software to analyze 533/30nm fluorescence intensity of 50,000cells under a medium 
flow rate (35uL/min). Utilizing scatter (SSC-A vs. FSC-A) gating and fluorescence intensity (SSC-
A vs. FL1), the percentage of cells expressing surface MHC-1 above the isotype background 
control for each treatment condition was determined. Three biologically independent replicates 
were carried out for each treatment condition and depicted as mean fold increase +/- s.d.. Statistical 
significance was determined using GraphPad Prism 7 by ANOVA with Tukey’s multiple 
comparison tests (95% confidence interval). 
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3.0   RESULTS AND ANALYSIS 
3.1  MONTORING MHC-1 PEPTIDE LOADING VIA FRAP ANALYSIS OF TAP1-
mNEONGREEN 
TAP1 is subunit one of transporter associated with antigen processing (TAP) located within the 
endoplasmic reticulum. TAP is responsible for the transport of peptides from the cytosol into the 
ER lumen. The MHC-1 peptide loading complex is formed by the interaction of active TAP, 
unfolded MHC-1, and chaperone proteins tapasin, calreticulin, and ERp57. TAP activity requires 
an independent ATP conformational change which induces the formation of the active peptide 
loading complex (27-29). Peptide loading is the rate limiting step to MHC-1 presentation where 
fluctuations in the size of intracellular antigen pool from alterations in protein translation or 
degradation effect the activity of TAP and the peptide loading complex (21,23,28). Reits et al. 
developed a method to indirectly quantify TAP activity via live cell fluorescence recovery after 
photobleaching (FRAP)(21-23). By tagging the c-terminal tail of TAP1 with a fluorescent 
fluorophore, mNeonGreen, the 2D lateral diffusion of TAP within the ER membrane can be 
calculated (D=ω2γ/4τD) from time of half-maximal fluorescence recovery. Active TAP diffuses 
slower as an open transporter that is associated with the larger peptide loading complex (21,23). 
Conversely, inactive TAP is closed and unassociated allowing faster diffusion. The diffusion 
coefficient is inversely proportional to the activity of TAP (21,23). 
A spot in the ER of TAP1-mNeonGreen stable U2OS cells was bleached and the recovery 
of fluorescence intensity overtime was monitored to calculate the diffusion coefficient.  To confirm 
that active translation is required for the activity of TAP, cells were treated with translation 
inhibitor cycloheximide (CHX) for one hour prior to FRAP experimentation. The diffusion 
coefficient increased in CHX treated ((1.65e-+/- 0.45) x10-10 cm2s-1) cells compared to the 
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untreated control ((1.28 +/- 0.51) x10-10 cm2s-1) demonstrating the expected decrease in TAP 
activity (Figure 5 left). Treatment with proteasome inhibitor MG132 should have also increased 
the diffusion coefficient by decreasing available the peptide pool. Unaccountably, the diffusion 
coefficient decreased ((1.01 +/- 0.42) x10-10 cm2s-1) compared to the untreated control suggesting 
increased TAP activity (Figure 5 left). Ionizing radiation damages both protein and DNA which 
disrupts translation both at the ribosomal level and the transcriptional level. To recapitulate the 
results of Reits et al. (2006) the effects of 5Gy radiation on TAP activity was measured at 1, 2, and 
4hrs post irradiation. The diffusion coefficient was significantly increased in the case of a 4hr 
treatment period with 5Gy ((1.71e-+/- 0.57) x10-10 cm2s-1) demonstrating the expected decrease in 
TAP activity (Figure 5 left).  
 ATM kinase activity in response to DNA damage has been implicated in contributing to 
the regulation of cap-dependent translation post ionizing radiation via the mTOR activity (Reits et al 
2006). ATM inhibition should prevent the downregulation of translation post radiation thereby 
increasing the intracellular peptide pool. To evaluate the effects of ATM inhibition, cells were 
treated with ATM inhibitor Ku55933 prior to radiation with physiologically relevant 2Gy and 5Gy 
as previously. The diffusion coefficient increased significantly from untreated ((1.3 +/- 0.53) x10-
10 cm2s-1) to 2Gy irradiated ((1.78e-+/- 0.79) x10-10 cm2s-1) indicating a decrease in TAP activity 
(Figure 5 right). Contrary to expectation, ATM inhibition alone increased the diffusion coefficient 
((1.74e-+/- 0.85) x10-10 cm2s-1) demonstrating decreased TAP activity and non-significantly 
decreased the effect of radiation when in combination ((1.64e-+/- 0.60) x10-10 cm2s-1) (Figure 5 
right). The combination of ATM inhibition with radiation was similarly ineffectual with 5Gy 
((1.70e-+/- 0.57) x10-10 cm2s-1) and ((1.96e-+/- 0.76) x10-10 cm2s-1) (Figure 5 right). The lack of 
effect in the combination of Ku55933 and radiation suggests that the dynamic range of this 
technique is not sufficient for this investigation.  
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3.2  QUANTIFICATION OF MHC-1 SURFACE EXPRESSION AFTER IONIZING 
RADIATION 
MHC-1 molecules present intracellular antigens to CD8+ cells at the cell surface for self-
recognition (27-30). The intracellular antigens are provided by the degradation of nascent peptides 
and represent the population of proteins being translated within the cell(27-30). Presentation of 
viral protein antigens or unrecognizable ‘neo-antigens’ (i.e. heavily mutated or ligated peptides) 
of cancer cells induce a cytotoxic T lymphocyte response resulting in the clearance of 
compromised cells (27-30). The landscape of antigen presentation available for CD8+ interactions 
is dependent on the expression of MHC-1 to the cell surface(27-30). 
Figure 5: FRAP analysis of TAP1-mNeonGreen U2OS stable cell line. 
Live-cell TAP1-NeonGreen U2OS stable cell imaging performed with a Nikon A1 Spectral Confocal 
microscope. The region of interest (ROI) was bleached with 488nm laser for 30s and imaged every 15s 
for 5mins to capture recovery. Drugs were administered as indicated and immediately prior to radiation. 
The 2-dimensional diffusion constant (D) of TAP1 was calculated individually for a minimum of 30 
cells. The average D of three independent experiments were plotted with standard deviation. Statistical 
significance was determined by ANOVA with Tukey’s multiple comparison tests (95% confidence 
interval). 
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The effects of DNA-damage response translation regulation post-radiation on of MHC-1 surface 
presentation were investigated via flow cytometry. For relevance to NSCLC, lung adenocarcinoma 
cell line A549 was irradiated with physiologically relevant 2Gy radiation after treatment with 
translation inhibitor CHX, proteasomal inhibitor MG132, ATR inhibitor AZD6738, or ATM 
inhibitor AZD0156 for 4, 24, and 48hr prior to flow analysis with FITC conjugated anti-HLA-I 
(MHC-1) antibody.  Due to the toxicity of CHX and MG132 treatment with these agents were 
limited to 4hr treatments periods prior to flow cytometry analysis. The fold change in mean 
fluorescence intensity for 50,000 cells under each treatment was calculated with respect to the 
untreated control and depicted as a mean of three independent experiments. At 4hrs post treatment 
there was no significant difference between the untreated control for any treatment group 
suggesting that this is too early of a time point to capture a shift in surface expression (Figure 6 
left). At 24hrs post treatment there are no significant differences, but there is a clear trend of 
decreased expression with the inhibition of translation (CHX) and proteasomal degradation 
(MG132) which both decrease the available antigen pool for MHC-1 loading (Figure 6 middle). 
Conversely, radiation and treatment with ATR inhibitor (AZD6738) increased MHC-1 surface 
expression (Figure 6 middle). At 48hrs, there was a 2.2-fold increase in MHC-1 surface 
presentation with ATR inhibition compared to the untreated control (Figure 6 middle and right). 
Under 2Gy radiation there is a non-significant increase over the untreated control; however, there 
is a non-significant increase from radiation alone to radiation in combination with ATR inhibition 
(1.44 vs. 1.87-fold change from untreated) (Figure 6 middle graph). The increase with radiation 
is most likely an increase in degradation proteins damaged by radiation. The increase with ATR 
inhibition alone suggests that DNA damage response signaling does contribute to protein 
translation or degradation. The increase in MHC-1 presentation from radiation alone to radiation 
in combination with ATR inhibition suggests that ATR does effect protein translation or 
degradation after ionizing radiation. However, there is no indication that the combined effect is 
not just a result of ATR inhibition alone. 
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Figure 6: MHC-1 Cell Surface Expression of A549 cells 
MHC-1 surface expression of A549 lung adenocarcinoma cells treated with the indicated drug and IR 
concentrations were analyzed via flow cytometry 4, 24, and 48hr post treatment. 50,000 cells per treatment 
group were analyzed in three independent experiments. The mean fold change in fluorescence intensity 
over the untreated control is depicted with standard deviation. Statistical significance was determined by 
ANOVA with Tukey’s multiple comparison tests (95% confidence interval). 
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4.0   DISUCSSION 
4.1  PITFALLS AND IMPROVEMENTS TO TAP1-mNEONGREEN FRAP 
EXPERIMENTATION 
Reits et al. (2000) developed a FRAP method to measure TAP mobility within the ER membrane 
as an indirect measurement of TAP activity and subsequent MHC-1 presentation. This method was 
adopted to indirectly investigate alterations in translation and MHC-1 loading by DNA-damage 
response signaling post ionizing radiation. U2OS stable cells expressing TAP1 c-terminally 
labeled with the monomeric fluorophore mNeonGreen were generated for FRAP experimentation. 
Initial control FRAP experimentation with translation inhibitor CHX indicated that there was a 
significant dynamic range to measure TAP activity with an increase in diffusion coefficient 
demonstrating decreased TAP activity (Figure 5 left). The lack of similar effect from proteosomal 
inhibition with MG132 was questionable and is potentially a result of using a different inhibitor. 
Reits et al. used lactacystin which is irreversible and is proteasome specific compared to the 
reversible MG132 which also targets calpain. They demonstrated that ATP depletion decreased 
TAP activity as a negative control while micro-injection of small peptides increased TAP activity 
as a positive control (21,23). Any further utilization of this technique would benefit from 
recapitulating these controls in conjunction with the CHX and proteasome inhibition negative 
controls.
Reits et al. (2006) observed a saturation of TAP activity that 1hr after radiation with 1, 7, 
and 25Gy which lasted longer in a dose dependent manner. In this investigation, 5Gy and 
physiologically relevant 2Gy produced a significant decrease in TAP activity after 4hrs of 
treatment period. A similar decrease in TAP activity was observed with ATM inhibition alone 
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which was unexpected. If ATM activity negatively regulates cap-dependent translation via the 
inhibition of mTOR in response to genome instability, it would be expected that ATM inhibition 
will have little or increased TAP activity demonstrated as a decrease the diffusion constant. The 
unexpected increase in diffusion with Ku55933 inhibition alone is most likely not off target effects 
as inhibition of mTOR should have a similar effect. This data suggests that ATM is positively 
regulating translation in the absence of radiation. In combination with radiation; however, the lack 
of effect may suggest that ATM regulation of translation is independent of signaling activated by 
ionizing radiation, or more likely that this technique is not robust enough for this purpose. This 
methodology provides a ‘macro’ analysis of lateral diffusion of TAP1 which reduces the sensitivity 
of the technique. The data acquired could be reanalyzed to look at changes in the size of the 
immobile fraction under different treatment conditions. Alterations in the immobile fraction would 
inform what fraction of TAP1 molecules within the region of interest are anchored as part of the 
MHC-1 peptide loading complex as opposed to measuring changes in the moving population.  
 Variability that could contribute to the lack of sensitivity of the current analysis can stem 
from issues inherent in live cell FRAP experimentation. The NIS-Elements4.0 software FRAP 
analysis is not capable of tracking a region of interest as the cell moves during image acquisition. 
As unbleached regions move in and out of the user designated region of interest fluctuations in the 
measurement of fluorescence intensity are introduced. To compensate moderate to large technical 
replicates (i.e. 30+ cells per treatment) are used. Additionally, it is difficult to maintain a standard 
size for the region of interest. During the photobleaching, the cell moves creating a larger region 
of interest that is unique to each cell.  To compensate the calculation for the diffusion coefficient 
takes the area variation into account.  
 In addition to typical live cell imaging pitfalls, the issue of TAP overexpression may 
contribute to unexpected results. In this investigation, overexpression TAP1-mNeonGreen which 
has a high potential of disrupting ER activity and the formation of functional TAP heterodimers 
of TAP1 and TAP2 subunits. An obvious improvement to this model is to introduce the 
mNeonGreen into the genome c-terminally to TAP1 via CRISPR/Cas9 genome editing(3). Other 
significant technical improvements would include co-localization data of mNeonGreen with an 
ER stain. In addition, the comparison of TAP1-mNeonGreen and TAP2-mNeonGreen to 
demonstrate that there is no subunit dependent functional difference that could contribute 
mechanistic alterations.  
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4.2  ATR INHIBITION IMPACT ON MHC-1 CELL SURFACE EXPRESSION 
Immune evasion is one of the hallmarks of cancer where tumor cells down regulate immune 
activating stimuli while up regulating immune deactivating stimuli (19). Current immunotherapy 
initiatives that target immune deactivating receptors (e.g. PD-L1 and B7) and have proven to be 
successful in NSCLC suggesting that treatment options that increase immune activating stimuli 
may improve tumor clearance. MHC-1 molecules presenting unrecognizable antigens, or ‘neo-
antigens’, can trigger the cytotoxic T lymphocyte response against tumor cells (27,30). The pool 
of antigens available for MHC-1 presentation to CD8+ T cells is dependent translation. Ionizing 
radiation disrupts translation via short term effects on the protein population and long term via 
genome instability (23). Inhibition of the DNA-damage response activated by radiation may 
disrupt translation inhibition post-radiation. Impeding negative regulation of translation during cell 
recovery could affect the rate MHC-1 presentation recovery after radiation and increase the 
percentage of ‘neo-antigens’ presented. 
In this investigation, inhibition of translation (CHX) and proteasomal degradation 
(MG132) for 4hrs induced a non-significant decrease in MHC-1 expression (Figure 6). The short 
treatment time was a compensation for cytotoxicity, longer incubations as lower concentrations 
would most likely result in a significant decrease in expression. Radiation alone produced a non-
significant increase in expression at 48hrs (Figure 6 right). Interestingly, ATR inhibition induced 
a significant increase in expression alone at 48hrs suggesting that the DNA-damage response and 
ATR specifically is involved in the negative regulation of translation (Figure 6 right). ATR 
inhibition non-significantly increased MCH-1 presentation in combination with radiation 
suggesting that improved immune recognition could contribute to the efficacy of the combinational 
therapy. A significant improvement to these experiments would be repeating with a lower 
concentration of ATR inhibitor closer to the IC50 of the compound.  
23 
5.0   FUTURE DIRECTIONS 
5.1  TMT-SILAC HYPERPLEXING AS AN ALTERNATIVE TO TAP1-
mNEONGREEN FRAP EXPERIMENTATION 
In our investigation the intended objective of the TAP1-mNeonGreen FRAP experimentation was 
to determine if post-ionizing radiation the DNA-damage response signaling negatively regulates 
translation. The rate of translation is known to directly correlate to the rate of MHC-1 loading and 
subsequent surface presentation. Inhibition of the DNA- damage response negative translation 
regulation could potentially increase MHC-1 surface presentation post radiation. FRAP analysis 
of TAP1-mNeonGreen provided an indirect method to monitor translation as a measurement of 
intracellular peptide transportation by TAP.  
In the interest of a more sensitive, direct quantitative approach, the mass spectrophotometry 
method TMT-SILAC hyperplexing was explored as an alternative technique to measure the impact 
of post-radiation DNA-damage response signaling on translation (52). Figure 7 depicts the 
simplified work flow for a TMT-SILAC hyperplexeing experiment. 2D cell lines are cultured in 
the appropriate unlabeled growth medium supplemented with standard antibiotics and dialyzed 
fetal bovine serum to reduce small molecule background (e.g. amino acids, hormones, or 
cytokines) present in the serum (52). To quantify the rate of translation, nascent peptides are 
labeled with heavy (15N/13C) L-lysine and L-arginine amino acids in a stable-isotope labeling in 
cell (SILAC) pulse (52). Cells are split into two populations, unlabeled and SILAC labeled, and 
treated with ATR inhibitor (AZD6738), ATM inhibitor (AZD0156), 
translation inhibitor (CHX), or vehicle control in combination with 2Gy ionizing radiation (Figure 
9 for schematic). For this investigation, the plating density for lung adenocarcinoma cell line H460 
was optimized to 3x105 cell/mL, 1.5x105cell/mL, or 0.5x105cell/mL to provided approximate cell 
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population at 24, 48, or 72hr timepoints (Figure 9). At various timepoints post SILAC-pulse and 
treatment, cells are harvested and lysed to generate high-quality peptides for mass 
spectrophotometry (52). Peptides from each timepoint per treatment group are then labeled with 
individual tandem mass tags (TMT) identifiers. TMT labeled timepoints for each treatment group 
are combined into one sample (52). The final sample provides a survey of the proteome of the cell 
under each treatment condition overtime. Subsequent tandem mass spectrophotometry (LC-
MS/MS) provides a readout for the time-resolved SILAC experiments which can be analyzed for 
the kinetics of translation (52). The increase in 15N/13C labeled lysine and arginine incorporation 
over time (identified by TMT label) provides a quantitative measure of translation (Figure 7) (52). 
In contrast, the decrease in unlabeled peptides over time (identified by TMT label) provides a 
quantitative measure of protein degradation (Figure 7) (52).    
TMT-SILAC hyperplexing is a technique that can be utilized to survey the impact of DNA-
damage response inhibition on the proteome during cell recovery post-radiation. It is a direct 
measurement of both the level of translation and what is being translated under different treatment 
conditions. As a mass spectrophotometry technique, it is also possible to track the translation of a 
protein under varying treatment conditions. Overall, the TMT-SILAC hyperplexing technique 
provides a highly sensitive and quantitative method to determine whether inhibition DNA-damage 
response signaling through ATM and ATR effects translation in the presence or absence of 
radiation. 
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Figure 8: Experimental Schematic for TMT-SILAC Hyperplexing 
To survey impact of DNA-damage response inhibition on the level and population of protein translation 
after radiation sixteen treatment groups will be analyzed. The eight treatment groups per media condition 
are further split into four drug treatments for irradiated and non-irradiated cells. Drug treaments are as 
follows: DMSO as the vehicle control, CHX as the positive control for translation inhibition, and 
AZD6738 or AZD0156 to inhibit ATR and ATM respectively. Peptides for each timepoint are labeled 
with unique TMT label for identification in LC-MS/MS analysis. 
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5.2  MECHANISTIC ANALYSIS OF DNA-DAMAGRE REPONSE REGULATION OF 
TRANSLATION 
The current investigation has endeavored to quantify the effect of post-radiation DNA-damage 
response signaling on translation and subsequent MHC-1 surface presentation. However, the 
techniques discussed so far do not interrogate the mechanism responsible for any shift in 
translation. TAP1-mNeonGreen FRAP experimentation and the proposed alternative TMT-SILAC 
hyperplexing measure fluctuations in the level of translation indirectly or directly, respectively. 
Flow cytometry analysis of the cell surface MHC-1 presentation measures the end-point of the 
impact of translation regulation post-radiation.  
Figure 9: Optimization of H460 Sub-culturing for TMT-SILAC Hyperplexing 
Lung adenocarcinoma H460 cell line was cultured in 15cm tissue culture dishes at 
8.4x104cells/mL seeding density for 80-90% confluency every 48hr. The number of cells 
in a single 15cm dish as 80-90% confluency was counted using the Millipore Cell Counter 
(60um filter) and plated in 10cm dishes at 0.5x105cell/mL, 1.5x105cell/mL, 2x105cell/mL, 
and 3x105cell/mL. At 24, 48, and 72 hours post-plating, cells were imaged using standard 
phase-contrast microscope and counted using the Millipore Cell Counter. Cell growth was 
graphed for each seeding density to determine which density produced similar cell counts 
at 24, 48, and 72 hrs. Two biological replications are depicted. 
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 Western blot analysis of translation initiation proteins is a simple, direct and method to 
examine the mechanism for how the DNA-damage response kinases ATM and ATR regulate 
translation. The mechanism should be compared in irradiated and non-irradiated in lung cancer 
cell lines (A549 and H460) under selective inhibition of ATR (AZD6738), ATM (AZD0156), or 
mTOR (Rapamycin). Western blot analysis of the phosphorylation of ATM, Chk2, ATR, Chk1, 
mTOR, and p53 will identify the signaling impact of DNA-damage response inhibition after 
radiation (12-18).  Western blot analysis of the phosphorylation of 4E-BP1, eIF4G, eIF4B, and 
40S small ribosomal protein S6 kinases will illustrate the impact of DNA-damage response 
inhibition on the regulation of translation (25,26). Radiation should increase DNA-damage 
response phosphorylation (ATM, ATR, Chk1, Chk2, p53) while decreasing translation activating 
phosphorylation (4E-BP1, eIF4G, eIF4B, S6Ks) and increasing inhibitory phosphorylation 
(mTOR). If the DNA-damage response regulates translation post-radiation, selective 
pharmacological inhibition should decrease or rescue the impact of radiation on the translation 
initiation complex.  
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APPENDIX 
Table 1: Abbreviations 
Abbreviation Definition 
DDR DNA damage response 
ATM Ataxia telangiectasia mutated 
ATR Ataxia telangiectasia mutated-related 
DSB Double strand break 
SSB Single strand break 
ssDNA Single-stranded DNA 
HR Homologous recombination 
NHEJ Non-homologous end joining 
NSCLC Non-small cell lung cancer 
FRAP Fluorescence recovery after photobleaching 
TAP Transporter associated with antigen processing 
MHC-1 Major histocompatibility complex class 1 
CTL Cytotoxic T lymphocyte 
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